The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Destructive Arthritis: From Prevention to Progression to Remission

Destructive Arthritis: From Prevention to Progression to Remission

March 19, 2019 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
NAR studio / shutterstock.com

NAR studio / shutterstock.com

CHICAGO—Josef S. Smolen, MD, professor of internal medicine and chair of the Department of Rheumatology, Vienna General Hospital, Austria, presented the prestigious Paul Klemperer, MD, Memorial Lecture at the 2018 ACR/ARHP Annual Meeting. Dr. Smolen, whose work is frequently cited, created the treat-to-target strategy for rheumatoid arthritis (RA).

You Might Also Like
  • Rheumatoid Arthritis Prevention, Remission & Treatment De-Escalation
  • EULAR 2012: Remission the New Normal for Rheumatoid Arthritis
  • Remission of Rheumatoid Arthritis Tied to Lower Risk of Metabolic Syndrome
Explore This Issue
March 2019
Also By This Author
  • Treg Cells May Orchestrate Muscle Repair after Injury

Dr. Smolen began by noting a simple examination of the pathology of RA reveals it is an inflammatory disease of the synovial membrane that leads to disability. Unfortunately, researchers still do not know what elicits the disease or which type of T cell is activated in the disease. Instead, most of the knowledge about RA centers on the final stages and the destructive work of the disease.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The realization that cells and cytokines are associated with the damage of RA still leaves unresolved the question of which abnormalities drive the progression of joint damage. The damage is clearly associated with inflammation, which is clinically visible as joint swelling and a higher affected joint count, Dr. Smolen explained. A confounder in this association is that patients with no swollen joints can have a high inflammatory serological response with no progression of joint damage.

Although composite measures of disease activity should include joint counts, Dr. Smolen stated, another important factor drives damage in RA: autoimmunity. Autoimmunity results in the formation of immune complexes that can activate complement and increase the inflammatory response. From this information, Dr. Smolen derived the hypothesis that it may be possible to prevent joint damage by interfering with inflammation and achieving remission.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

From this goal, Dr. Smolen explained, stem the questions: How is the progression of joint damage best stopped? Is it possible to achieve early remission and sustained remission? When attempting to answer these questions, rheumatologists discovered even patients who achieved remission shortly before their second year had some disease progression.1 In contrast, patients who were able to achieve an earlier and durable remission were able to halt the progression of joint damage. Further research suggested tumor necrosis factor inhibitors were the most effective drugs for inhibiting joint damage.2

Disease Progression

Typically, RA outcomes are measured by the ACR70 criteria. What rheumatologists began to see, however, was patients could more easily achieve remission than they could meet the ACR70 criteria. This suggested remission was somehow separate from the response to treatment documented by the ACR70. Dr. Smolen explained this difference is probably at least partly due to the way the hand is constructed. The patient with early disease has disability as a result of stiffness or pain from disease activity, and the disability can be fully reversed with treatment. In contrast, a patient with longstanding disease has disability, not from disease activity, but from the damage itself. The disability in this patient is the consequence of joint destruction. So this latter patient will experience permanent disability in the face of clinical remission.

Dr. Smolen explained that a patient with a modified Sharp score of 50 or higher will likely not show much response to treatment because such a patient has physical disability associated with cartilage damage. The treatment goal for patients with RA becomes to stop inflammation as quickly as possible to optimize physical function.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, Rheumatoid Arthritis Tagged With: 2018 ACR/ARHP Annual Meeting, Treat-to-TargetIssue: March 2019

You Might Also Like:
  • Rheumatoid Arthritis Prevention, Remission & Treatment De-Escalation
  • EULAR 2012: Remission the New Normal for Rheumatoid Arthritis
  • Remission of Rheumatoid Arthritis Tied to Lower Risk of Metabolic Syndrome
  • Effects of Obesity on Sustained Remission in Early RA

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.